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ABSTRACT
Acute and chronic renal dysfunction are common after hematopoietic stem cell transplantation (HSCT).
Although the pathology of chronic HSCT nephropathy is well described, the histologic changes that accom-
pany acute renal dysfunction after HSCT are less well known because renal biopsies are rarely undertaken in
the peritransplantation period. Archival renal tissue from consecutive HSCT recipients who died and under-
went autopsy at a single center during an 8-year period was studied. Abnormalities of renal pathology were
described, and associations of histologic abnormalities with clinical events were systemically studied. Abnor-
malities of renal histology were common among the 26 patients in this study. The 3 most common histologic
abnormalities were glomerular sclerosis (19/26; 73%), tubular epithelial atypia (19/26; 73%), and tubular
calcification (18/26; 69%). Tubulitis (16/24; 67%) and interstitial fibrosis (16/26; 62%) were also frequently
observed. Clinical veno-occlusive disease was not associated with histologic evidence of thrombotic microan-
giopathy in the kidney at autopsy. Also, clinical graft-versus-host disease was not associated with renal
tubulitis. Unexpectedly, the proportion of patients with tubular atrophy (54%) or interstitial fibrosis (62%) was
high, considering the young age of the patients at transplantation and their normal pretransplantation
creatinine clearance. Well-recognized histologic abnormalities are common in the kidneys of patients who die
after HSCT. Although we did not demonstrate associations of these histologic changes with clinical variables
before death, larger studies with prospectively collected renal tissue are warranted.
© 2003 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Treatment-related toxicity limits the success of
utologous and allogeneic hematopoietic stem cell
ransplantation (HSCT). Infection and bleeding dur-
ng the period of marrow aplasia and treatment-re-
ated organ dysfunction remain major causes of non-
elapse mortality.
Renal insufﬁciency is a common organ dysfunc-
ion after HSCT. Acute renal insufﬁciency, deﬁned as
doubling of the pretransplantation serum creatinine
n the ﬁrst 4 weeks after transplantation, occurs in 5%
o 64% of HSCT recipients [1-4]. Approximately
5% to 50% of adult HSCT recipients who develop m
B&MTcute renal insufﬁciency require dialysis, and the re-
uirement for dialysis confers a grave prognosis [1].
any factors contribute to acute renal insufﬁciency
fter HSCT. Patients may have preexisting renal in-
ury from their underlying disease, and prior therapy
nd high-dose chemotherapy and radiation adminis-
ered in the preparative regimen may directly cause
enal damage [5-7]. Rapid cytolysis of tumor and nor-
al marrow can cause tumor lysis syndrome with
enal injury due to hyperphosphatemia, as well as
rate and xanthine nephropathy [8]. Infusion of cryo-
reserved marrow or blood progenitor cells may lead
o renal insufﬁciency by several mechanisms. Di-oi:10.1016/S1083-8791(03)00243-Xethyl sulfoxide, a cryoprotectant, may cause in vivo
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hemolysis and hemoglobinuria [9], and cellular debris
accompanying cryopreserved cells causes direct glo-
merular damage and proteinuria [10]. Posttransplan-
tation infections often lead to acute renal insufﬁciency
because they may be accompanied by hypotension and
renal hypoperfusion. Antimicrobials used for prophy-
laxis and treatment of infections are also commonly
nephrotoxic. Finally, several HSCT-speciﬁc syn-
dromes of organ dysfunction also affect the kidney. A
hallmark of hepatic veno-occlusive disease is marked
renal sodium avidity with renal dysfunction [3,11], and
renal insufﬁciency is also a cardinal feature of post-
HSCT hemolytic-uremic syndrome [12].
The pathology of renal injury in the immediate
peritransplantation period is not well described. Renal
biopsy is rarely undertaken early after transplantation,
because patients are often severely thrombocytopenic.
It is also unclear whether establishing the pathology of
renal injury in the peritransplantation period would
result in a speciﬁc treatment not otherwise considered.
In the longer term, 57% of patients in 1 series had
a decrease of 20% in glomerular ﬁltration rate at 2
years after HSCT [13]. Chronic renal dysfunction
may result from incomplete recovery from acute peri-
transplantation renal insults, as well as from the effects
of treatment of chronic graft-versus-host disease
(GVHD) [14] and total body irradiation [13,14]. Al-
though some suggest that cyclosporine nephrotoxicity
is not a problem in this group [14,15], nephrotoxicity
accompanying chronic GVHD is likely secondary to
the use of calcineurin inhibitors rather than to GVHD
itself [16].
In this report, we describe the renal pathology of
26 consecutive recipients of HSCT who died and
underwent autopsy at a single transplant center. As
prespeciﬁed hypotheses, we sought to examine whether
clinical veno-occlusive disease was associated with renal
thrombotic microangiopathy and whether acute and
chronic GVHD were associated with renal tubulitis.
PATIENTS AND METHODS
Consecutive patients who died and underwent au-
topsy after high-dose therapy and HSCT at the
Queen Elizabeth II Health Sciences Centre between
June 1992 and January 2000 were included in this
study. Renal pathology was assessed by a renal pathol-
ogist (R.G.) blinded to the clinical ﬁndings associated
with each case. Kidneys were examined at autopsy by
light microscopy with sections stained with hema-
toxylin and eosin, periodic acid-Schiff, Masson
trichrome, and silver methenamine. Tissue retrieved
from parafﬁn blocks was used for electron microscopy
in cases of suspected glomerulopathy. The presence or
absence of the following abnormalities was noted:
thrombotic microangiopathy, glomerulopathy, glo-
merular sclerosis, tubular cell degeneration, tubular
epithelial atypia (tubular epithelial cell pleomorphism
and hyperchromasia), tubular calciﬁcation, tubular at-
rophy, tubulitis (lymphomonocytic inﬁltrate invading
nonatrophic tubules), interstitial ﬁbrosis, and arterio-
lar hyalinization. If the constellation of ﬁndings in a
specimen was consistent with a speciﬁc renal diagno-
sis, this was also noted.
Clinical data were retrospectively extracted from
the medical record by using a standardized form with-
out knowledge of the pathologic ﬁndings. Acute and
chronic GVHD and hepatic veno-occlusive disease
were assessed clinically according to established crite-
ria [17-19]. In this study, acute renal dysfunction was
deﬁned as a 50% increase in serum creatinine con-
centration (compared with the serum creatinine at
transplantation) that was not present 2 weeks before
death but that occurred in the 2 weeks immediately
preceding death. Chronic renal dysfunction was de-
ﬁned as a 50% increase in serum creatinine above
serum creatinine at transplantation present 2 weeks
before death and sustained until the time of death.
Statistical analyses were performed with SPSS
(SPSS Inc., Chicago, IL). The Student t test was used
to describe differences between groups for continuous
variables, and the Fisher exact test was used for dis-
crete variables. Relationships among histologic obser-
vations were explored by using Spearman’s  test with-
out adjustment for multiple comparisons. Kaplan-
Meier analysis was used to summarize the interval
between transplantation and death. All statistical tests
were 2 tailed, and P  .05 was considered signiﬁcant.
RESULTS
Three hundred twenty-one patients (autologous,
n  180; related allogeneic, n  130; unrelated allo-
geneic, n  11) underwent HSCT at the Queen Eliz-
abeth II Health Sciences Centre between June 1992
and January 2000, and 113 (35%) of these patients
died within 3 years after HSCT. All 26 patients who
died and underwent autopsy at the transplant center
during this time are the subject of this report.
The patients’ clinical characteristics at transplan-
tation are shown in Table 1. All patients had a mea-
sured creatinine clearance of 60 mL/min before
transplantation (mean, 120 mL/min; range, 67-172
mL/min). Most patients (20/26; 77%) underwent al-
logeneic transplantation, and all allogeneic recipients
received cyclosporine and methotrexate as GVHD
prophylaxis.
The causes of death and comorbidities of the 26
patients are shown in Table 2. Nonrelapse mortality
(23/26; 88%) was the major cause of death, as ex-
pected, because the study was limited to patients who
underwent autopsy at the transplant center. One pa-
S. El Seisi et al.
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tient had clinical evidence of post-HSCT hemolytic-
uremic syndrome before death.
The abnormalities of renal pathology of the 26
patients are shown in Table 3. The 3 most common
histologic abnormalities were glomerular sclerosis
(19/26; 73%), tubular epithelial atypia (19/26; 73%),
and tubular calciﬁcation (18/26; 69%). The pattern of
sclerosis was global in all cases of glomerular sclerosis,
and the percentage of involved glomeruli was always
25%. Mild tubulitis (16/24; 67%) and interstitial
ﬁbrosis (16/26; 62%) were also frequently observed.
Three clusters of abnormal renal pathologies were
noted. Arteriolar hyalinization was associated with tu-
bular cell degeneration (  0.55; P  .003) and
tubular atrophy (  0.39; P  .05). Tubular cell
degeneration and tubulitis were associated with glo-
merular sclerosis ( 0.41, P .04; and  0.41, P
.05, respectively), and interstitial ﬁbrosis was associ-
ated with arteriolar hyalinization (  0.42; P  .04).
Two prespeciﬁed hypotheses of possible clinico-
pathologic associations were examined. The ﬁrst hy-
pothesis was that clinical veno-occlusive disease may
be associated with histologic evidence of thrombotic
microangiopathy in the kidney at autopsy. Although
clinical veno-occlusive disease was present in 6 (23%)
of 26 patients and histologic features of thrombotic
microangiopathy (Figure 1) were common in the renal
specimens at autopsy (12/26; 46%), no statistically
signiﬁcant association of these entities was noted (P 
.37). The second hypothesis was that clinical GVHD
may be associated with renal tubulitis at autopsy (Fig-
ure 2). GVHD manifests in other organs with a lym-
Table 1. Patient Characteristics at Transplantation
Variable Data
Age, y, mean (range) 37 (17-56)
Male sex, n (%) 19 (73%)
Indication for transplantation
Acute leukemia 8
Lymphoma 6
Myeloma 5
Myelodysplasia 2
Chronic leukemia 2
Solid tumor 2
Aplastic anemia 1
Type of transplant, n (%)
Autologous 6 (23)
Related allogeneic 16 (62)
Unrelated allogeneic 4 (15)
Pretransplantation creatinine clearance,
mL/min, mean (range)
120 (67-172)
Etoposide conditioning, n (%) 5 (19)
Cyclophosphamide conditioning, n (%) 23 (88)
Total body irradiation, n (%) 5 (19)
Use of cyclosporine, n (%) 20 (77)
Table 2. Causes of Death and Comorbidities
Variable Data
Interval between transplantation and death,
mo, median (range) 3 (0.5-24)
Clinical acute or chronic GVHD, n (%) 10/20 (50)
Clinical veno-occlusive disease, n (%) 6/26 (23)
CMV-related disease, n (%) 3/26 (12)
Serum creatinine 2 wk before death, mol/
L, median (range) 97 (46-324)
Serum creatinine immediately before
death, mol/L, median (range) 187 (40-739)
Acute renal dysfunction, n (%) 15 (58)
Chronic renal dysfunction, n (%) 7 (27)
Causes of death, n (%)
Nonrelapse 23 (88)
Noninfectious pulmonary disease 9
Infection 8
GVHD 2
Bleeding 2
Multiorgan failure 2
Relapse 3 (12)
CMV indicates cytomegalovirus.
Table 3. Renal Histologic Abnormalities
Renal Histologic Abnormality n (%)
Thrombotic microangiopathy 12 (46)
Glomerular sclerosis 19 (73)
Tubular cell degeneration 8 (31)
Tubular atrophy 14 (54)
Tubular epithelial atypia 19 (73)
Tubulitis* 16 (67)
Tubular calcification 18 (69)
Interstitial fibrosis 16 (62)
Arteriolar hyalinization 12 (46)
*Two cases were not evaluable for the presence of tubulitis because
autolysis precluded interpretation of this abnormality (1 patient)
and because of a marked inﬁltrate of polymorphonuclear cells (1
patient).
Figure 1. Renal thrombotic microangiopathy in a 38-year-old
woman who died 7 months after an autologous transplantation for
metastatic breast cancer. Before death, she had clinical evidence of
posttransplantation hemolytic-uremic syndrome (stain, hematoxylin
and eosin; magniﬁcation, 400).
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phocytic inﬁltrate of affected tissue. We reasoned that
renal tubulitis may result from an inﬁltration of donor
lymphocytes into the recipient’s kidney, thus repre-
senting a renal manifestation of GVHD. However, we
found no association of clinical acute or chronic
GVHD with renal tubulitis (P  .66).
Tubular epithelial atypia was a common histologic
abnormality (19/26; 73%) in the kidneys of the 26
patients. Etoposide, cyclophosphamide, and total
body irradiation used in high doses as conditioning in
HSCT are associated with well-described renal toxic-
ities. However, we found no association between these
agents and renal tubular epithelial atypia (P .59, 1.0,
and .59, respectively). There was also no histologic
evidence of viral cytopathic effects in the renal speci-
mens to account for the frequent observation of tubu-
lar epithelial atypia.
Two well-described clinicopathologic syndromes
were observed among the 26 patients. One patient who
underwent autologous transplantation for metastatic
breast cancer died 7 months after HSCT of noninfec-
tious pulmonary interstitial disease. At autopsy, she had
glomerular basement membrane thickening consistent
with membranous glomerulonephritis. Another patient
who underwent a related allogeneic HSCT for myeloma
had extensive chronic GVHD requiring long-term im-
munosuppression and died of disseminated aspergillosis.
At autopsy, extensive renal inﬁltration with polymorpho-
nuclear leukocytes and fungal elements was noted, com-
patible with the antemortem diagnosis of overwhelming
fungal infection.
DISCUSSION
Acute renal dysfunction is common among pa-
tients undergoing HSCT. Multiple factors contribute
to this renal dysfunction, including preexisting renal
injury, direct effects of conditioning chemotherapy
and radiation, complications of the infusion of cryo-
preserved cells, tumor lysis syndrome, and the effects
of infection and its treatment. Hepatic veno-occlusive
disease and post-HSCT hemolytic-uremic syndrome
are also associated with renal insufﬁciency.
Despite the prevalence of clinical renal dysfunc-
tion in the peritransplantation period, little is known
of the accompanying histologic changes in the kidney.
Renal biopsy is rarely undertaken, because patients are
often severely thrombocytopenic and clinicians judge
that unexpected and treatable diagnoses are unlikely
to be discovered.
We have described a spectrum of histologic ab-
normalities in the kidneys of 26 consecutive patients
who died after HSCT and underwent autopsy at a
single center. We found that renal histologic abnor-
malities were frequent in this population; thrombotic
microangiopathy, tubular epithelial atypia, and arte-
riolar hyalinization were commonly observed. Given
the complex clinical course these patients experienced
in the days before their death, the expected renal
lesion from hypoxia, ischemia, and toxic effects is
acute tubular necrosis, which is characterized by a
focal loss of tubular epithelial cells that leaves areas of
denuded basement membranes [20]. We observed a
high incidence of a number of abnormalities that were
not in keeping with classic acute tubular necrosis.
First, tubulitis was seen in 67% of patients. Renal
tubulitis without atrophy is an uncommon histologic
diagnosis usually seen in renal allograft rejection and
interstitial nephritis. In our patient group, no speciﬁc
clinical factor was associated with this histologic ab-
normality at autopsy. In particular, renal tubulitis was
not associated with GVHD. Second, thrombotic mi-
croangiopathy occurred in 46% of patients. The fre-
quent histologic observation of renal thrombotic mi-
croangiopathy was also unexpected because only 1
patient had clinical evidence of hemolytic-uremic syn-
drome. This was not associated with veno-occlusive
disease, a syndrome characterized histologically by
hepatic microangiopathy and thrombosis. Although
calcineurin inhibitors such as cyclosporine have been
associated with post-HSCT hemolytic-uremic syn-
drome, we were unable to demonstrate an association
between the use of cyclosporine and histologic
changes of thrombotic microangiopathy in the kidney.
However, the power of this analysis is limited because
only 6 patients did not receive cyclosporine in our
study.
Tubular epithelial atypia was another common
abnormality of renal histology in this patient group.
We hypothesized that tubular epithelial atypia may be
related to speciﬁc cytotoxic agents or radiation used in
the conditioning regimen. Cyclophosphamide is well
known to affect the uroepithelium through its toxic
Figure 2. Renal tubulitis in a 51-year-old man who died 5 months
after a matched sibling allogeneic transplantation for myeloma.
Before death, he had extensive chronic graft-versus-host disease
(stain, hematoxylin and eosin; magniﬁcation, 400).
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metabolite acrolein [21]. Etoposide is renally excreted
and has been associated with renal dysfunction, and
total body irradiation has well-described injurious ef-
fects on the kidney [22]. However, we did not observe
an association between any of these agents and tubular
epithelial atypia, nor was there evidence of viral cyto-
pathic effects in the kidneys at autopsy to account for
the tubular epithelial atypia. This frequent histologic
abnormality remains unexplained.
The proportion of patients in this series with tu-
bular atrophy or interstitial ﬁbrosis was high (54% and
62%, respectively), considering their young age and
normal creatinine clearance before transplantation.
These histologic changes are typically chronic and
unlikely to be related to immediate antemortem
events. Although HSCT and the associated interven-
tions and comorbidities may directly cause chronic
renal injury, treatments administered before HSCT
may also lead to subtle chronic renal injury that is not
identiﬁed by measurement of creatinine clearance be-
fore transplantation.
One patient in this series had histologic features of
membranous nephropathy. Her original diagnosis was
breast cancer, and although the association between
membranous nephropathy and solid-organ tumors is
well known [23], the coexistence of this histologic
pattern with breast cancer in particular has not been
previously described. Membranous nephropathy was,
however, observed by Imai et al. [14] in 2 of 9 cases
after HSCT examined histologically; this raises the
possibility of an association with HSCT rather than
the underlying malignancy.
There are several limitations of our study. The
histologic studies were limited by the use of archival
autopsy material, which precluded immunologic and
electron microscopic studies. The small number of
autopsies performed at our center limited the power
of the study to examine associations between clinical
variables and histologic abnormalities, so our inability
to document certain associations may have been solely
due to the small patient sample size. Finally, although
the study included consecutive patients who died after
HSCT and underwent autopsy, it necessarily repre-
sents a selected group of patients. Patients who died
after clinically apparent relapse would be less likely to
have undergone autopsy, and patients who died at
their local hospital or at home were not included in
this study.
In summary, we have shown that well-recognized
histologic abnormalities are common in the kidneys of
patients who die after HSCT. In this small study, we
did not demonstrate an association of renal throm-
botic microangiopathy with either veno-occlusive dis-
ease or post-HSCT hemolytic-uremic syndrome. Re-
nal tubulitis was not associated with acute or chronic
GVHD. Larger studies with prospectively collected
renal tissue for more detailed histologic study are
warranted.
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